Related to CureVac, Sanofi Pasteur, and In-Cell-Art Collaborate on €33.1M DARPA-Supported Vaccine Program

• Crucell to Use Pepscan’s CLIPS Technology for Development of Infectious Disease Vaccines
  
• Medicago Achieves $3.8M Milestone under DARPA Contract to Build Vaccine Plant
  
• MabVax Wins $1.8M SBIR Grant to Support Phase II Sarcoma Vaccine Trial
  
• FDA Approves Sanofi Pasteur’s Meningococcal Vaccine for Children Aged 9–23 Months
  
• Institute of Human Virology Awarded $23.4M to Fund Clinical Trials of HIV Vaccine
  
• U.S. Army Awards $45.5M Contract to PPD for Clinical Trial Management
  
• Singapore’s Regulatory Body Clears Emergent’s BioThrax Anthrax Vaccine
  
• Sorrento Wins Second NIAID Grant of $600K to Develop Qourum Quenching Antibacterial
  
• Avaxia Gets Two-Year $2.9M Biodefense Award from BARDA
  
• Eureka Wins $750K SBIR Grant to Develop Technology for Detecting Anthrax Variants
  
• GeoVax Receives Latest Tranche of $19.6M NIAID Funding for HIV Vaccine
  
• CSL Negotiates Option to Pevion’s Candida Vaccine for Australia and New Zealand
  
• GeoVax Labs Receives $0.8M Funding Boost from NIAID to Progress HIV Vaccine
  
• Rhenovia and French Army Awarded €1.15M to Develop Neurotoxin Biosimulation Platform
  
• Aura Raises $4.5M and Signs CRADA for Diagnostic and Therapeutic Nanoparticle Platform
  
• Aduro BioTech Wins $250K in SBIR Grants and Contract with UNM for Vaccine Development
  
• BARDA to Give Neumedicines $17M to Progress Radiation Countermeasure
  
• BARDA Provides $56.3M to Support Five Drugs Against Radiation Injury
  
• Emergent Wins Potentially $1.25M Anthrax Vaccine Supply Contract
  
• Ablitech Gets $2M DoD Grant for R&D into Heterotopic Ossification